AtriCure to Present at the Morgan Stanley Global Healthcare Conference
August 18 2017 - 5:00PM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
(LAA) management, today announced that it will present at the
Morgan Stanley Global Healthcare Conference at the Grand Hyatt in
New York on Tuesday, September 12, 2017. Management is scheduled to
present at 5:15 p.m. Eastern Time. A live audio webcast of the
presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at ir.atricure.com. A replay of the
presentation will be available for 180 days following the
presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide. For more information, visit AtriCure.com or
follow us on Twitter @AtriCure.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170818005514/en/
AtriCure, Inc.Andy Wade, 513-755-4564Senior Vice President and
Chief Financial Officerawade@atricure.comorGilmartin GroupLynn
Pieper Lewis, 415-937-5402Investor
Relationslynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024